Clover Health (CLOV) Shows 'Stock Market Detached From Reality', SPACs Need More Supervision, Says Billionaire Barry Sternlicht
- Wall Street closes mixed, S&P 500 ends off record high
- Private Sector Employment Increased by 330,000 Jobs in July, Missing Expectations
- General Motors (GM) Misses on Profit Estimates as Bolt EV Recall Weighs on Earnings, Challenging Chip Situation and 'Cautious' Profit Outlook Pulling Shares Lower Says Analyst
- Exclusive-U.S. developing plan to require foreign visitors to be vaccinated -official
- Softbank-Backed Zymergen (ZY) Crashes Over 70% as CEO Departs, Product Revenue Not Possible in 2021 and 'Immaterial' in 2022, At Least 6 Firms Downgrade
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
U.S. billionaire and co-founder of Starwood Capital Group Barry Sternlicht said special purpose acquisition companies (SPACs) need increased supervision from the U.S. Securities and Exchange Commission (SEC), citing Clover Health Investments Corp. (NASDAQ: CLOV) as a sign of a bubble.
“The stock market is detached from reality,” Sternlicht said at Bloomberg’s Qatar Economic Forum. “Clover Health Care is basically a fraud, is trading at $16 a share, and it keeps going up. The more you say it is going out of business, the higher the stock goes.”
Sternlicht noted five different SPAC mergers he’s been involved in since the start of the year, adding he hoped the trend had reached its peak.
“There is a trickle of deals getting done. I hope it remains a trickle. I doubt it will remain a trickle until the SEC tightens the process up because the projections that are in these -- there has to be someone saying they are reasonable because they are really misleading investors.”
SPAC deals experienced a boom in 2020 as companies saw an easier and less-scrutinized method to go public, in contrast to a traditional initial public offering (IPO).
“If you could breathe you could raise a SPAC,” added Sternlicht.
One of his SPACs, Jaws Juggernaut Acquisition Corp., secured $240 million in IPO last week and plans to use the proceeds to make acquisitions in the wireless communications industry.
U.S. Medicare Advantage insurer Clover went public last year with the help of SPAC advocate Chamath Palihapitiya. Since then, Clover has faced criticism from the investment research firm Hindenburg Research and is set to face a probe by the SEC.
In response, Clover argued that the Hindenburg report “is rife with ad-hominem attacks, sweeping inaccuracies and gross mischaracterization. It belies a desperate attempt for publicity while sacrificing any regard for the truth.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kredivo Announces Plans to Become Publicly Traded Company via Merger with VPC Impact Acquisition Holdings II (VPCB)
- Ecoark Holdings, Inc (ZEST) Prices 3.5M Share Direct Offering at $5.75/sh
- NexTier Oilfield Solutions (NEX) Acquires Alamo Pressure Pumping for $268M
Create E-mail Alert Related CategoriesMomentum Movers, SPAC, Short Sales, Trader Talk
Related EntitiesDefinitive Agreement, IPO, Hindenburg Research, SPAC
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!